KD019: Clinical Trials

1 trial of KD019, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Terminated 1

Follow KD019: new trials by email Literature Review of KD019 trials Research Report on KD019

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
KD019, Erlotinib - Carcinoma, Non-Small-Cell Lung
Phase 3TerminatedKadmon Corporation, LLC82011-12-142022-05-13

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)

Sponsors

Kadmon Corporation, LLC (1)

Countries

United States (1)